Vaccination does not increase the risk of multiple sclerosis (MS) in children and adolescents within five years, a study found. Instead, there was a trend toward a lower risk of pediatric-onset MS in vaccinated children. This in line with earlier findings that vaccination is not a risk factor for…
vaccination
Getting the Bacillus Calmette-Guerin (BCG) vaccine to protect against tuberculosis (TB) or having latent (inactive) TB in young adulthood aren’t linked to the risk of developing multiple sclerosis (MS), a Norwegian study found. The study, “BCG vaccination and multiple sclerosis risk: A Norwegian cohort study,” was published in…
Certain COVID-19 vaccines do not appear to worsen the symptoms of multiple sclerosis (MS), and may provide protection for at least six months after a booster dose, according to a study in Spain. The study specifically examined mRNA vaccines, or those that use a piece of RNA to teach…
Among multiple sclerosis (MS) patients on rituximab, higher B-cell counts are predictive of a better antibody-based response to a vaccine for COVID-19, according to a new Swedish study. “In our study, the B-cell level in patients given Rituximab was the only factor that influenced the ability to form antibodies…
Getting the Pfizer-BioNTech vaccine for COVID-19 does not increase the risk of multiple sclerosis (MS) relapses in the two months following vaccination, according to a new study. The results support recommending COVID-19 vaccines for people with MS, its researchers said. “The incidence of relapses in the 2 months before and…
A conversational bot is being developed at the University of Illinois at Urbana-Champaign (UIUC) to promote COVID-19 vaccinations among people with multiple sclerosis (MS) who are hesitant to take the vaccine. The project is meant to provide accessible digital health information about the vaccines to more vulnerable populations…
Vaccines are not a risk factor for multiple sclerosis (MS), a large data analysis spanning more than 12,250 MS patients in Germany shows. Fewer vaccinations were given to people who — five years later — would be diagnosed with MS, compared to those who would be diagnosed with…
Few things scare me. I mean, truly frighten me to my core. While I flee from bees and scream at spiders, I have been both stung and bitten. Scary movies, no matter how asinine, freak me out. Being alone in the dark invokes vivid imagination. Jason, Freddy, and Michael Myers.
Girls given the quadrivalent human papillomavirus (HPV4) vaccination, commercialized as Gardasil, showed no increased risk of developing autoimmune diseases like multiple sclerosis (MS), according to a new Canadian study. The time since vaccination and the number of vaccine doses given also did not correlate with diagnoses of such disorders, supporting…
Ocrevus (ocrelizumab), a recently approved therapy for relapsing and primary progressive multiple sclerosis (MS), is now on the U.S. market, but research into its use is far from over. Several clinical trials, sponsored by Ocrevus’ developer Genentech or its parent company Roche, are looking at various aspects of the treatment. Multiple Sclerosis…
Two studies recently published in the journal Science Translational Medicine, revealed a possible new vaccine treatment for JC virus with important implications for multiple sclerosis (MS) treatment. The studies are entitled “JC polyomavirus mutants escape antibody-mediated neutralization” and “Broadly neutralizing human…